Showing posts with label Treatments. Show all posts
Showing posts with label Treatments. Show all posts

Tuesday, 30 July 2013

Treatments for tuberculosis, cancer will likely improve following breakthrough in detecting DNA mutations

Main Category: Tuberculosis
Also Included In: Cancer / Oncology;  Genetics
Article Date: 30 Jul 2013 - 0:00 PDT Current ratings for:
Treatments for tuberculosis, cancer will likely improve following breakthrough in detecting DNA mutations
not yet ratednot yet rated

The slightest variation in a sequence of DNA can have profound effects. Modern genomics has shown that just one mutation can be the difference between successfully treating a disease and having it spread rampantly throughout the body.

Now, researchers have developed a new method that can look at a specific segment of DNA and pinpoint a single mutation, which could help diagnose and treat diseases such as cancer and tuberculosis. These small changes can be the root of a disease or the reason some infectious diseases resist certain antibiotics. The findings were published online in the journal Nature Chemistry.

"We've really improved on previous approaches because our solution doesn't require any complicated reactions or added enzymes, it just uses DNA," said lead author Georg Seelig, a University of Washington assistant professor of electrical engineering and of computer science and engineering. "This means that the method is robust to changes in temperature and other environmental variables, making it well-suited for diagnostic applications in low-resource settings."

DNA is a type of nucleic acid, the biological molecule that gives all living things their unique genetic signatures. In a double strand of DNA, known as a double helix, a series of base pairs bond and encode our genetic information. As genomics research has progressed, it's clear that a change of just one base pair - a sequence mutation, an insertion or a deletion - is enough to trigger major biological consequences. This could explain the onset of disease, or the reason some diseases don't respond to usual antibiotic treatment.

Take, for example, tuberculosis ?" a disease that's known to have drug-resistant strains. Its resistance to antibiotics often is due to a small number of mutations in a specific gene. If a person with tuberculosis isn't responding to treatment, it's likely because there is a mutation, Seelig said.

Now, researchers have the ability to check for that mutation preventatively.

Seelig, along with David Zhang of Rice University and Sherry Chen, a UW doctoral student in electrical engineering, designed probes that can pick out mutations in a single base pair in a target stretch of DNA. The probes allow researchers to look in much more detail for variations in long sequences - up to 200 base pairs ?" while current methods can detect mutations in stretches of up to only 20.

"In terms of specificity, our research suggests that we can do quadratically better, meaning that whatever the best level of specificity, our best will be that number squared," said Zhang, an assistant professor of bioengineering at Rice University.

The testing probes are designed to bind with a sequence of DNA that is suspected of having a mutation. The researchers do this by creating a complimentary sequence of DNA to the double-helix strand in question. Then, they allow molecules containing both sequences to mix in a test tube in salt water, where they naturally will match up to one another if the base pairs are intact. Unlike previous technologies, the probe molecule checks both strands of the target double helix for mutations rather than just one, which explains the increased specificity.

The probe is engineered to emit a fluorescent glow if there's a perfect match between it and the target. If it doesn't illuminate, that means the strands didn't match and there was in fact a mutation in the target strand of DNA.

The researchers have filed a patent on the technology and are working with the UW Center for Commercialization. They hope to integrate it into a paper-based diagnostic test for diseases that could be used in parts of the world with few medical resources.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our tuberculosis section for the latest news on this subject.

The research was funded by the National Institutes of Health, the National Science Foundation and the Department of Defense's Advanced Research Projects Agency.

University of Washington

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

University of Washington. "Treatments for tuberculosis, cancer will likely improve following breakthrough in detecting DNA mutations." Medical News Today. MediLexicon, Intl., 30 Jul. 2013. Web.
30 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Treatments for tuberculosis, cancer will likely improve following breakthrough in detecting DNA mutations'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Sunday, 28 July 2013

Finding may lead to new treatments for neurodegenerative disease and stroke

Main Category: Neurology / Neuroscience
Also Included In: Stroke;  Rehabilitation / Physical Therapy
Article Date: 25 Jul 2013 - 1:00 PDT Current ratings for:
Finding may lead to new treatments for neurodegenerative disease and stroke
5 starsnot yet rated

In degenerative brain diseases and after stroke, nerve cells die while their support cells activate the brain's immune system to cause further damage. Now Jonathan Gilthorpe, Adrian Pini and Andrew Lumsden at the MRC Centre for Developmental Neurobiology at King's College London, have found that a single protein, histone H1, causes these distinct outcomes.

The research passed peer review within a week of being published in F1000Research, where Jan-Marino Ramirez, of the University of Washington, called the work "a very important contribution to our understanding of neurodegenerative disease and the response of the brain to injury" in his public referee report. He also noted that he is "confident that this study will be a much cited contribution to the field of traumatic brain injury".

The most unexpected finding in this study is that a histone protein is responsible for neuronal damage. "Histone H1 partners with DNA in the cell nucleus and has been thought of as harmless," explain the authors, "The surprise came when we discovered that it can be released from brain cells upon injury, killing healthy nerve cells and activating the damaging immune response".

The research team is now working on ways to suppress these harmful actions, which may lead to the development of new treatments for neurodegenerative disease and stroke.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our neurology / neuroscience section for the latest news on this subject.

Extracellular histone H1 is neurotoxic and drives a pro-inflammatory response in microglia [v1; ref status: indexed] F1000Research 2013, 2:148 (doi: 10.12688/f1000research.2-148.v1)

Faculty of 1000

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

1000, Faculty of. "Finding may lead to new treatments for neurodegenerative disease and stroke." Medical News Today. MediLexicon, Intl., 25 Jul. 2013. Web.
25 Jul. 2013. APA

Please note: If no author information is provided, the source is cited instead.


'Finding may lead to new treatments for neurodegenerative disease and stroke'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam). We reserve the right to amend opinions where we deem necessary.

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here

Sunday, 14 July 2013

New Treatment For Management Of Advanced Prostate Cancer After First-Line Hormonal Treatments And Docetaxel Chemotherapy Failure, Available In UK

Main Category: Prostate / Prostate Cancer
Also Included In: Regulatory Affairs / Drug Approvals
Article Date: 12 Jul 2013 - 2:00 PDT Current ratings for:
New Treatment For Management Of Advanced Prostate Cancer After First-Line Hormonal Treatments And Docetaxel Chemotherapy Failure, Available In UK
not yet rated5 stars

Available now, XTANDI TM (enzalutamide) has been licensed for the treatment of men with advanced prostate cancer whose disease has become resistant to first-line hormonal treatments and has progressed following docetaxel chemotherapy[i], marking an important step in managing prostate cancer, which is the most common cancer among males in the UK.[ii] The UK licence has been granted based on pivotal trial data showing a 37% reduction of the risk of death versus placebo for patients taking enzalutamide during the study.[iii] Enzalutamide was also shown to be generally well tolerated.[iii] Enzalutamide is the latest in a new generation of drugs which can prolong and improve the quality of life for men with incurable advanced prostate cancer.[iii]

Professor Johann de Bono, Professor of Experimental Cancer Medicine at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, and Global Chief Investigator in the AFFIRM trial said: "Enzalutamide is a much needed development in prostate cancer treatment and will provide a new option for the increasing number of men with advanced prostate cancer in the UK, whose disease has become resistant to first-line hormonal treatments and who have had docetaxel chemotherapy. Enzalutamide has already demonstrated a positive impact on quality of life whilst increasing the life-span of patients with this common disease. Its use will bring significant benefits, establishing it as a key component of advanced prostate cancer treatment in the UK."

Prostate cancer is the second most common cause of cancer death in men in the UK.[ii] Although early stage disease can often be cured, when prostate cancer spreads to other parts of the body (known as advanced or metastatic prostate cancer), most commonly the bones, the disease is incurable.[iv] In patients who present with advanced disease, 72% will die within 5 years of diagnosis.[v]

Many men with advanced disease eventually develop resistance to first-line hormone treatment; this is called castration-resistant prostate cancer (CRPC).[vi] On average, 10-20% of prostate cancer patients develop CRPC within approximately 5 years of follow up, and of those almost 84% have metastatic disease at the time of diagnosis.[vii]

Enzalutamide is a once-daily, oral treatment administered without the need for routine product- specific monitoring.i Steroids are not required to be taken with enzalutamide, however, they can be prescribed at the judgement of a doctor.[i]

Enzalutamide works differently from other treatments for patients with advanced prostate cancer: enzalutamide works at three steps in the androgen receptor (AR) signalling pathway within the cancer cells stopping the cancer growing.[i] In advanced prostate cancer enzalutamide has been shown to decrease cancer cell growth and can cause cancer cell death.[i,iii]

The granting of the UK licence for enzalutamide follows the submission of data from the AFFIRM trial - a multinational study evaluating enzalutamide (160 mg/day) versus placebo in 1,199 men with advanced prostate cancer who were previously treated with docetaxel-based chemotherapy.[iii] From today, enzalutamide will provide UK clinicians with a treatment option which improves overall survival by an average of 4.8 months versus placebo, whilst potentially helping to maintain a good quality of life.i,iii Enzalutamide is available in England via the Cancer Drugs Fund.[viii]

About advanced prostate cancer

Advanced (or metastatic) prostate cancer refers to a cancerous tumour which has extended beyond the prostate and moved to other parts of the body, most commonly the bones.[ix,x] These 'advanced' prostate tumours cannot be cured.iv Treatment of advanced prostate cancer usually involves reducing testosterone either by surgical or medical methods.iv However, advanced prostate cancer can become resistant to this type of therapy at which stage it is known as metastatic castration- resistant prostate cancer (mCRPC).[xi] When prostate cancer is advanced, treatment can usually be given to slow the progression of the cancer, relieve symptoms and improve quality of life.[xii]

About enzalutamidei

Enzalutamide is a novel, oral, once-daily androgen receptor signalling inhibitor which works in three distinct ways: it inhibits 1) testosterone binding to androgen receptors; 2) nuclear translocation of androgen receptors; and 3) DNA binding and activation by androgen receptors.

Enzalutamide is licensed in Europe for the treatment of adult men with mCRPC whose disease has progressed on or after docetaxel therapy.[i]

Enzalutamide was licensed by the U.S. Food and Drug Administration on August 31, 2012 for the treatment of patients with mCRPC who have previously received docetaxel therapy.[xiii]

About AFFIRM[iii]

The phase III AFFIRM trial is a randomised, double-blind, placebo-controlled, multinational trial evaluating enzalutamide (160 mg/day) versus placebo in 1,199 men with progressive mCRPC who were previously treated with docetaxel-based chemotherapy. Enrolment was completed in November 2010 and the interim analysis was triggered at 520 events. The median age of study participants was 69 years at baseline.

The AFFIRM study was conducted at sites in the United States, Canada, Europe, Australia, South America and South Africa.

Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our prostate / prostate cancer section for the latest news on this subject.

References

[i] European Medicines Agency, Xtandi (enzalutamide) Summary of Product Characteristics, 2013

[ii] Cancer Research UK, Prostate Cancer, available at http://publications.cancerresearchuk.org/downloads/Product/CS_KF_PROSTATE.pdf, last accessed May 2013

[iii] Scher H I, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, New England Journal of Medicine, N Engl J Med 2012; 367:1187-1197

[iv] Cancer Research UK, Treatment options for prostate cancer, last accessed June 2013

[v] National Cancer Institute, SEER Fast Statistics, last accessed June 2013.

[vi] Macmillan Cancer Support. Treatment for advanced prostate cancer/hormonal therapy, last accessed June 2013

[vii] Kirby M, Hurst C, Crawford ED. Characterising the castration-resistant prostate cancer. Int J Clin Pract 2011;65:1180-92

[viii] NHS England, National Cancer Drugs Fund List, updated June 18th 2013, last accessed June 2012

[ix] Prostate cancer UK, what is advanced prostate cancer?, last accessed May 2013

[x] Cancer Research UK: The Stages of Prostate Cancer, last accessed June 2013

[xi] Maluf, F,Smaletz O, Herchenhorn, D, Castration-resistant prostate cancer: systemic therapy in 2012, last accessed June 2013 ?

[xii] Macmillan Cancer Support. Treatment for advanced prostate cancer, last accessed June 2013

[xiii] FDA, Xtandi (enzalutamide), prescribing information, 2012

Astellas

Please use one of the following formats to cite this article in your essay, paper or report:

MLA

Astellas. "New Treatment For Management Of Advanced Prostate Cancer After First-Line Hormonal Treatments And Docetaxel Chemotherapy Failure, Available In UK." Medical News Today. MediLexicon, Intl., 12 Jul. 2013. Web.
14 Jul. 2013. APA
Astellas. (2013, July 12). "New Treatment For Management Of Advanced Prostate Cancer After First-Line Hormonal Treatments And Docetaxel Chemotherapy Failure, Available In UK." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/263256.php.

Please note: If no author information is provided, the source is cited instead.


'New Treatment For Management Of Advanced Prostate Cancer After First-Line Hormonal Treatments And Docetaxel Chemotherapy Failure, Available In UK'

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



View the original article here